Eli Lilly (LLY): Uptrend Intact as GLP-1 Leadership Fuels GrowthEli Lilly and CompanyBATS:LLYfinvestnomicsEli Lilly continues to hold firmly above its 20- and 50-day EMAs after a healthy retracement, with clear buying interest emerging at the 20 EMA. This price behavior suggests the strong uptrend remains intact and is likely to continue driven by flagship diabetes treatment Mounjaro, obesity drug Zepbound, and the anticipated launch of orforglipron. The company plans to introduce a pill version of its weight-loss therapy in mid-2026, a move analysts expect will help Lilly maintain its leadership in the GLP-1 market. Financial performance has been exceptional, with Q3 revenue and EPS growth of 54% and 480%, respectively. Profitability remains robust, with ROE at 97% and ROIC at 34% in Q3, alongside net margins holding around 30%. The balance sheet is solid, supported by healthy liquidity with a current ratio of approximately 2.0x and a manageable debt profile, reflected in a debt-to-equity ratio of about 1.8x. Eli Lilly’s sustained outperformance is underpinned by a wide economic moat, reinforcing both its strong fundamentals and prevailing bullish trend. LLY